Some of the key players in the Mantle Cell Lymphoma Market therapeutics market include Juno Therapeutics, Nurix, Janssen Biotech, AbbVie/Genentech, TG Therapeutics, Roche, Eli Lilly and Company, Takeda Oncology, Starton Therapeutics, Incyte Corporation, BeiGene, Newave Pharmaceutical, Eli Lilly and Company, and others.
DelveInsight's "Mantle Cell Lymphoma Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Mantle Cell Lymphoma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Mantle Cell Lymphoma drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Mantle Cell Lymphoma treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Mantle Cell Lymphoma: An Overview
Non-Hodgkin’s lymphoma (NHL) is a cancer of the lymphatic system which is a part of the body’s immune system and it occurs when tumors develop from white blood cells (lymphocytes). Many types of cancers can spread to the lymph nodes, but only cancers that start in the lymph tissue are considered lymphomas.
There are many types of NHL, Mantle Cell Lymphoma being one of them, classified by how the cells look under a microscope. Most types of NHL are categorized as either B-cell lymphoma or T-cell lymphoma. Mantle Cell Lymphoma takes over the body’s B Cells, which normally make antibodies to fight infections and the cancerous B cells grow out of control and make lymph nodes larger. The cancer can spread to the patient’s bone marrow, liver, and gastrointestinal tract as well.
As per Lynch et al., (2022), Mantle Cell Lymphoma is a rare subtype of B-cell non-Hodgkin lymphoma (NHL) with an annual incidence of one case per 200,000 people. MCL comprises around 5% of all.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Mantle Cell Lymphoma pipeline therapies. It also thoroughly assesses the Mantle Cell Lymphoma market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Mantle Cell Lymphoma drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Mantle Cell Lymphoma Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Mantle Cell Lymphoma epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Mantle Cell Lymphoma epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Mantle Cell Lymphoma Epidemiology, Segmented as -
-
Total Incident Cases of MCL in 7MM [2019–2032]
-
Total Diagnosed Cases of MCL in 7MM [2019–2032]
-
Total Age-specific Cases of MCL in 7MM [2019–2032]
-
Total Gender-specific Cases of MCL in 7MM [2019–2032]
-
Total Treated Cases of MCL in the 7MM [2019–2032]
-
Total Stage-specific Cases of MCL in the 7MM [2019–2032]
Mantle Cell Lymphoma Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Mantle Cell Lymphoma market or expected to be launched during the study period. The analysis covers the Mantle Cell Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Mantle Cell Lymphoma drugs based on their sale and market share.
The report also covers the Mantle Cell Lymphoma pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Mantle Cell Lymphoma companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Mantle Cell Lymphoma Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/mantle-cell-lymphoma-market
Mantle Cell Lymphoma Therapeutics Analysis
The dynamics of the Mantle Cell Lymphoma market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the diseases, incremental healthcare spending across the world, and the expected launch of emerging therapies during the forecast period.
Several major pharma and biotech companies are developing therapies for Mantle Cell Lymphoma. Currently, Abbvie is leading the therapeutics market with its Mantle Cell Lymphoma drug candidates in the most advanced stage of clinical development.
"On Jan. 27, 2023, Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), announced that the U.S. Food and Drug Administration (FDA) approved Jaypirca™ (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor. Jaypirca was approved under the FDA's Accelerated Approval pathway based on the response rate from the open-label, single-arm, international, Phase 1/2 study, called the BRUIN trial."
"On June 14, 2023, Nurix Therapeutics, Inc. (Nasdaq: NRIX) announced the presentation of clinical and preclinical data from its targeted protein degradation programs, NX-5948 and NX-2127, which are being evaluated in ongoing Phase 1 clinical trial in patients with relapsed/refractory B cell malignancies. These data are being presented at the 17th International Conference on Malignant Lymphoma (ICML) which is being held June 13-17, in Lugano, Switzerland."
Mantle Cell Lymphoma Companies Actively Working in the Therapeutics Market Include
-
Juno Therapeutics
-
AbbVie
-
BeiGene
-
Eli Lilly and Company
-
Genentech
-
Incyte Corporation
-
Janssen Biotech
-
Newave Pharmaceutical
-
Nurix
-
Roche
-
Starton Therapeutics
-
Takeda Oncology
-
TG Therapeutics
And Many Others
Emerging and Marketed Mantle Cell Lymphoma Therapies Covered in the Report Include:
-
Venetoclax: AbbVie
-
Daratumumab: Janssen Pharmaceutical
-
NVG-111 (Novalgen),
-
HMPL-760: Hutchison medipharma
-
Orelabrutinib: Beijing InnoCare Pharma Tech
-
LOXO-338: Eli Lilly and Company
And Many Others
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/mantle-cell-lymphoma-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Mantle Cell Lymphoma Competitive Intelligence Analysis
4. Mantle Cell Lymphoma Market Overview at a Glance
5. Mantle Cell Lymphoma Disease Background and Overview
6. Mantle Cell Lymphoma Patient Journey
7. Mantle Cell Lymphoma Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Mantle Cell Lymphoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Mantle Cell Lymphoma Unmet Needs
10. Key Endpoints of Mantle Cell Lymphoma Treatment
11. Mantle Cell Lymphoma Marketed Therapies
12. Mantle Cell Lymphoma Emerging Drugs and Latest Therapeutic Advances
13. Mantle Cell Lymphoma Seven Major Market Analysis
14. Attribute Analysis
15. Mantle Cell Lymphoma Market Outlook (In US, EU5, and Japan)
16. Mantle Cell Lymphoma Companies Active in the Market
17. Mantle Cell Lymphoma Access and Reimbursement Overview
18. KOL Views on the Mantle Cell Lymphoma Market
19. Mantle Cell Lymphoma Market Drivers
20. Mantle Cell Lymphoma Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/mantle-cell-lymphoma-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Acute Lymphocytic Leukemia (ALL) Market
"Acute Lymphocytic Leukemia (ALL) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Acute Lymphocytic Leukemia market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Acute Lymphocytic Leukemia market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
